%PDF-1.4
%
3 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 114>>stream
xs
w3T04PI2P0T5T0 q,LBr4\rSRS*C2R3K*scK,A:KR4C@&@\C 2
endstream
endobj
1 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 114>>stream
xs
w3T04PI2P0T5T0 q,LBr4\rSRS*C2R3K*scK,A:KR4C@&@\C 2
endstream
endobj
4 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 114>>stream
xs
w3T04PI2P0T5T0 q,LBr4\rSRS*C2R3K*scK,A:KR4C@&@\C 2
endstream
endobj
6 0 obj
<>stream
iText 4.2.0 by 1T3XT2016-03-16T18:02:50+05:30Arbortext Advanced Print Publisher2017-10-10T09:27:08-07:002017-10-10T09:27:08-07:00uuid:8addd02c-2a8d-4824-a074-0375b52bef83uuid:9735c38c-787b-4f5b-aca7-e8422204bc96JournalAmyloid© 2017 Informa UK Limited, trading as Taylor & Francis Group1350-61291744-2818001-31310.1080/13506129.2017.1385453https://doi.org/10.1080/13506129.2017.1385453application/pdf10.1080/13506129.2017.1385453en-USPitfalls in conducting prospective trials in stage III cardiac amyloidosis – experience from the REVEAL studyInforma UK Ltd.Amyloid, 2017. doi: 10.1080/13506129.2017.1385453Phillips Elizabeth H.Nash StephenAdedayo ToyinWhelan Carol J.Fontana MariannaMahmood ShameemLachmann Helen J.Gillmore Julian D.Smith PaulClifton-Hadley LauraHawkins Philip N.Wechalekar Ashutosh D.VoR2017-10-06truewww.tandfonline.com10.1080/13506129.2017.1385453www.tandfonline.comtrue2017-10-0610.1080/13506129.2017.1385453
endstream
endobj
7 0 obj
<>stream
x+ |
endstream
endobj
8 0 obj
<>stream
xS**T0T0 Bi yJ%
endstream
endobj
9 0 obj
<>stream
x+ |
endstream
endobj
10 0 obj
<>stream
xS*
R
endstream
endobj
11 0 obj
<>stream
x+ |
endstream
endobj
12 0 obj
<>stream
xS**T0T0 Bi y8#
endstream
endobj
13 0 obj
<>stream
x+ |
endstream
endobj
14 0 obj
<>stream
xS**T0T0 Bi yA$
endstream
endobj
16 0 obj
<>stream
xZKϯG|?`y
">>$kI#G~THvO
Z"3MzngxMPw*tP9$Qw7`UUt[.KThCu~1b=unN-<00Ex{᷶}|~Ne{2\/8z'dڜ7'uKp[xc}P^b"(pv\w*ș}a`87X;{lT5HG{YO^iZR䟴4{0IbQ%귗v/^4W߿' =0q4zC#@5UGZ|qH(hzӷe6p t[^(ސ)2wf]A&u1 ԘBFG2}b;hR[d-'7i$ᶠ%+
VX-HSȆAvDXjQ]0AfDZ@:w`LõɀMHh'NsyC9+mkymm<